The Oncology Research Unit is a dedicated centre of excellence focused on advancing cancer care through high-quality clinical research. The team comprises experienced oncologists and clinical coordinators who work together to design and conduct clinical trials that explore innovative treatment options, diagnostics, and supportive care interventions. With good infrastructure and a patient-centred approach, the unit ensures ethical and rigorous trial conduct in alignment with global research standards. It aims to provide patients access to cutting-edge therapies while contributing to the global fight against cancer.
Ongoing and completed clinical trials span a range of cancer types, including breast, lung, gastrointestinal, and haematological malignancies. The unit is committed to translating scientific discoveries into tangible improvements in patient outcomes, and fostering an environment that supports innovation, learning, and compassionate care.
Researchers Team
Dr. Minish Jain
Sr.No.
Study Title
Principal Investigator
Duration
Ongoing / Closed
01
A prospective, randomised, double blind, multicentric, parallel group Phase-III clinical study to evaluate the efficacy, safety, and immunogenicity of BP01 (Bevacizumab) versus EU approved Avastin® along with chemotherapy XELOX in metastatic colorectal cancer patients.
A prospective, multicentric, single arm, Open label, Phase IV Clinical study to evaluate safety and efficacy of DenosuRelTM containing Denosumab manufactured by Reliance Life sciences Pvt. Ltd. India for prevention of skeletal related events in patients with bone metastases from solid tumours. (RLS/PMS/2021/01)
Prospective, multi-centre, randomized, open-label, two arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-023/ AvastinTM intravenously in patients with Metastatic colorectal cancer”
A multicentre, open label, randomised, two-treatment, two-period, two-sequence, single dose, cross-over bioequivalence study of Doxorubicin Hydrochloride (Pegylated liposomal) concentrate for solution for infusion 20 mg/10mL (2 mg/ml) of Dr. Reddy’s Laboratories Ltd, India, with that of Caelyx® 2 mg/mL [Doxorubicin Hydrochloride (Pegylated Liposomal) concentrate for solution for infusion (20 mg/10mL)] of Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium in advanced ovarian cancer and/or metastatic breast cancer patients under fed condition.
A prospective, multicentre, randomised, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer
